Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma
Rozeman, E. A., Hoefsmit, E. P., Reijers, I. L. M., Saw, R. P. M., Versluis, J. M., Krijgsman, O., Dimitriadis, P., Sikorska, K., van de Wiel, B. A., Eriksson, H., Gonzalez, M., Torres Acosta, A., Grijpink-Ongering, L. G., Shannon, K., Haanen, J. B. A. G., Stretch, J., Ch’ng, S., Nieweg, O. E., Mallo, H. A., Adriaansz, S., Kerkhoven, R. M., Cornelissen, S., Broeks, A., Klop, W. M. C., Zuur, C. L., van Houdt, W. J., Peeper, D. S., Spillane, A. J., van Akkooi, A. C. J., Scolyer, R. A., Schumacher, T. N. M., Menzies, A. M., Long, G. V., Blank, C. U.
Published in Nature medicine (01.02.2021)
Published in Nature medicine (01.02.2021)
Get full text
Journal Article
MART-1 TCR gene-modified peripheral blood T cells for the treatment of metastatic melanoma: a phase I/IIa clinical trial
Rohaan, M.W., Gomez-Eerland, R., van den Berg, J.H., Geukes Foppen, M.H., van Zon, M., Raud, B., Jedema, I., Scheij, S., de Boer, R., Bakker, N.A.M., van den Broek, D., Pronk, L.M., Grijpink-Ongering, L.G., Sari, A., Kessels, R., van den Haak, M., Mallo, H.A., Karger, M., van de Wiel, B.A., Zuur, C.L., Duinkerken, C.W., Lalezari, F., van Thienen, J.V., Wilgenhof, S., Blank, C.U., Beijnen, J.H., Nuijen, B., Schumacher, T.N., Haanen, J.B.A.G.
Published in Immuno-oncology technology (01.09.2022)
Published in Immuno-oncology technology (01.09.2022)
Get full text
Journal Article
1184PDResults of a phase I trial with MART-1 T cell receptor modified T cells in patients with metastatic melanoma
Rohaan, M W, Gomez-Eerland, R, Foppen, M H Geukes, van Zon, M, de Boer, R, Bakker, N A M, Pronk, L M, Sari, A, Mallo, H A, van de Wiel, B A, Lalezari, F, Beijnen, J H, Nuijen, B, van Tinteren, H, van Thienen, J V, Blank, C U, Wilgenhof, S, Schumacher, T N, van den Berg, J H, Haanen, J B A G
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
1313PD3-year relapse-free survival (RFS), overall survival (OS) and long-term toxicity of (neo)adjuvant ipilimumab (IPI) + nivolumab (NIVO) in macroscopic stage III melanoma (OpACIN trial)
Blank, C U, Versluis, J M, Reijers, I L M, Sikorska, K, van Houdt, W J, van Thienen, J V, Adriaansz, S, Mallo, H A, van Tinteren, H, van de Wiel, B A, Grijpink-Ongering, L G, Bruining, A, Haanen, J B A G, van Akkooi, A C J, Schumacher, T N, Rozeman, E A
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article